Development, Manufacture and Clinical Application of Drug Conjugates in Cancer Therapy
This special issue belongs to the section "Immunology and Immunotherapy".
Special Issue Information
Dear Colleagues,
Recent years have seen a surge in the development and clinical application of small molecules targeting mutated or overexpressed proteins in cancer cells. Despite initial clinical successes, inevitably these treatments fail as cancer cells, through various mechanisms, develop resistance to these compounds. In this situation, the opportunity to specifically deliver potent cytotoxic drugs to cancer drugs by their conjugation to cancer cell targeting biologicals because more cogent.
Over the last two decades, a great deal of effort has been invested in the development and testing of targeted drug delivery systems (TDDS). They have demonstrated several important advantages over free drug chemotherapy. Thus far, however, only antibody-drug conjugates have succeeded in reaching the clinical stage.
This Special Issue will present up-to-date and critically discussions of TDDS. The issue will cover the use of antibodies, peptides, proteins, and other structures as drug carriers; issues of manufacture and regulation of carrier-drug-conjugates; and clinical and diagnostic applications.
Prof. Dr. Michael A. Firer
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biology of drug delivery via carrier-drug conjugates
- overcoming cancer cell drug resistance with carrier-drug conjugates
- carrier alternatives—antibodies, peptides, proteins, small ligands, nanostructures
- technologies for discovering novel targeting agents
- carrier-drug conjugation chemistries
- manufacturing and regulatory issues of carrier-drug conjugates
- clinical experience with carrier-drug conjugates for cancer therapy
- expanding the clinical opportunities for carrier-drug conjugates
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Published Papers
Biomedicines - ISSN 2227-9059